| For: | Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL. Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2025; 31(48): 114355 [PMID: 41480329 DOI: 10.3748/wjg.v31.i48.114355] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i48/114355.htm |
| Number | Citing Articles |
| 1 |
Esteban Fuentes-Valenzuela, Irene Chivato Martín-Falquina , José Antonio Olmos Jerez , María del Carmen López-Martín , Almudena Calvache , Marina Gil Santana , Carlos Castaño Milla , Alicia Bejerano Domínguez. Short and medium-term outcomes of ustekinumab biosimilar in patients with Crohn�s disease in na�ve patients and after switching from originator. Revista Española de Enfermedades Digestivas 2026; doi: 10.17235/reed.2026.11878/2026
|
| 2 |
Qin-Jian Wang, Zheng Zhu, Guang-Rong Lu. Letter to the Editor: Missing mechanistic data and small inflammatory bowel disease cohorts: Key barriers in ustekinumab switching. World Journal of Gastroenterology 2026; 32(19): 117160 doi: 10.3748/wjg.v32.i19.117160
|
| 3 |
Shannon L. Piche, Michelle D. Becker, Shubha Bhat, Linda L. Huang, Sunanda V. Kane. Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations. Advances in Therapy 2026; 43(7) doi: 10.1007/s12325-026-03584-6
|